Relay Therapeutics Stock Investor Sentiment
| RLAY Stock | USD 3.34 0.05 1.52% |
Slightly above 51% of Relay Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Relay Therapeutics suggests that some traders are interested. Relay Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Relay Therapeutics' earnings reports, geopolitical events, and overall market trends.
Relay |
Relay Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Relay Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Relay Therapeutics that are available to investors today. That information is available publicly through Relay media outlets and privately through word of mouth or via Relay internal channels. However, regardless of the origin, that massive amount of Relay data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Relay Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Relay Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Relay Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Relay Therapeutics alpha.
Relay Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 400 shares by Peter Rahmer of Relay Therapeutics at 4.38 subject to Rule 16b-3 | 12/27/2024 |
2 | Disposition of 32156 shares by Peter Rahmer of Relay Therapeutics at 4.15 subject to Rule 16b-3 | 01/02/2025 |
3 | Disposition of 32177 shares by Peter Rahmer of Relay Therapeutics at 4.3 subject to Rule 16b-3 | 01/03/2025 |
4 | Disposition of 16576 shares by Peter Rahmer of Relay Therapeutics at 4.45 subject to Rule 16b-3 | 01/06/2025 |
5 | Relay Therapeutics Reaches New 12-Month Low - Whats Next - MarketBeat | 01/16/2025 |
6 | Disposition of 50000 shares by Patel Sanjiv of Relay Therapeutics at 9.16 subject to Rule 16b-3 | 01/17/2025 |
7 | Disposition of 125000 shares by Patel Sanjiv of Relay Therapeutics at 4.52 subject to Rule 16b-3 | 01/21/2025 |
8 | Disposition of 125000 shares by Patel Sanjiv of Relay Therapeutics at 4.8 subject to Rule 16b-3 | 01/22/2025 |
9 | Disposition of 125000 shares by Patel Sanjiv of Relay Therapeutics at 4.78 subject to Rule 16b-3 | 01/23/2025 |
10 | Disposition of 33688 shares by Adams Brian of Relay Therapeutics at 4.63 subject to Rule 16b-3 | 01/28/2025 |
11 | Disposition of 46407 shares by Bergstrom Donald A of Relay Therapeutics at 4.55 subject to Rule 16b-3 | 01/29/2025 |
12 | Disposition of 20791 shares by Adams Brian of Relay Therapeutics at 4.42 subject to Rule 16b-3 | 01/30/2025 |
13 | BlackRock, Inc. Expands Stake in Relay Therapeutics Inc with Significant Share Acquisition | 02/05/2025 |
14 | Disposition of 140182 shares by Patel Sanjiv of Relay Therapeutics at 3.85 subject to Rule 16b-3 | 02/11/2025 |
15 | Disposition of 75324 shares by Patel Sanjiv of Relay Therapeutics at 3.7 subject to Rule 16b-3 | 02/13/2025 |
16 | Can These Two Major Healthcare Conferences Reveal Relay Therapeutics Next Big Move - StockTitan | 02/24/2025 |
17 | What To Expect From Relay Therapeutics Inc Q4 2024 Earnings | 02/25/2025 |
18 | Relay Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary - TradingView | 02/27/2025 |
19 | Down -31.1 percent in 4 Weeks, Heres Why You Should You Buy the Dip in Relay Therapeutics | 03/05/2025 |
20 | HC Wainwright Reaffirms Buy Rating for Relay Therapeutics | 03/07/2025 |
21 | E Fund Management Co. Ltd. Grows Stock Position in Relay Therapeutics, Inc. | 03/10/2025 |
22 | Disposition of 348 shares by Adams Brian of Relay Therapeutics at 7.7 subject to Rule 16b-3 | 03/12/2025 |
23 | Relay Therapeutics SWOT analysis promising drug faces stiff competition - Investing.com | 03/17/2025 |
Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.